Founded in 1993
  Year: 2003 | Volume: 11 | Issue: 3 | Pages: 139-142
  Review Article
  PRIMARY ENDOCRINE THERAPY OF LOCALLY ADVANCED BREAST CANCER PATIENTS
Zora NESKOVIC-KONSTANTINOVIC
  DOI:
  Abstract:
  Primary endocrine therapy has been traditionally reserved for elderly and unfit locally advanced breast cancer patients (LABC patients.). In this group, the primary endocrine therapy could not be adequately compared to primary chemotherapy. Rare studies of primary endocrine therapy, and careful subgroup analyses of their results, showed that primary endocrine therapy could achieve at least the similar magnitude of response rate, compared to primary chemotherapy, in selected patients' population. Thus, the primary treatment with tamoxifen in steroid receptor (SR)-positive LABC patients became the standard arm in current studies of primary endocrine therapy. Several questions, concerning the use of endocrine primary treatment in routine clinical practice, should be answered, including the definition of optimum endocrine agents, biomarkers for prediction of response, and patients' selection criteria.
  Key words: Breast Neoplasms; Antineoplastic Agents, Hormonal; Neoadjuvant Therapy; Combined Modality TherapyBreast Neoplasms; Antineoplastic Agents, Hormonal; Neoadjuvant Therapy; Combined Modality Therapy
  Read full text in PDF [Full Text]
Next article

Previous article

Table of contents

Browse all Volumes

Search all Volumes
By keywords
By authors

  Search AoO for:
 

  Related articles in AoO:
 
About Journal | Editorial Board | Editorial Policy | Instructions for Authors | Open Access | Advertising | Payed issues | Article Submission Charge | Contact
Founder, owner and publisher: Oncology Institute of Vojvodina, Serbia
Online since 1997 (Abstracts only); 2000 (Abstracts and Full text)
ISSN: 0354-7310 eISSN: 1450-9520